Insider transactions

Bradley J PhD Bolzon

CIK 1354345 · last filed 2022-06-10

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$149.02M
Companies
6
Total Filings
68
Lifetime Open-Market Net
-$112.05M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

CRSP price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
ONE SANSOME STREET
SUITE 3630
SAN FRANCISCO, CA 94104
Related Filers
Charles M Warden — 28 joint filings, latest 2016-06-10
Rebecca B Robertson — 23 joint filings, latest 2016-05-24
Versant Venture Capital II, LP — 19 joint filings, latest 2015-05-11
Versant Affiliates Fund II-A, LP — 17 joint filings, latest 2015-05-11
Versant Side Fund II, LP — 17 joint filings, latest 2015-05-11
Versant Ventures II LLC — 17 joint filings, latest 2015-05-11
Barbara N Lubash — 14 joint filings, latest 2016-06-10
William J Phd Link — 8 joint filings, latest 2009-09-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRSP Director 148,831 $49.99 $7.44M -$125.65M 33 2022-06-10
GLUE Director 6,799,115 $10.63 $72.27M $3.00M 2 2021-06-30
BDTX Director 21,851 $1.75 $38.2K $5.33M 22 2021-06-22
CRISPR Therapeutics AG (PZRX) Delisted Director 27,724 — — $1.69M 6 2017-12-27
INGN 10%+ Owner 7,723 $6.87 $53.1K -$425.7K 3 2015-05-11
FLXN Director 2,899,115 $23.88 $69.22M $4.00M 2 2014-03-04

Recent Filings · Page 7 of 7

68 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2017-06-02 CRISPR Therapeutics AG (PZRX) Delisted Grant (A) — $0 EDGAR
2016-12-23 CRISPR Therapeutics AG (PZRX) Delisted Mixed +6,669,699 $2.25M EDGAR
2016-10-20 CRISPR Therapeutics AG (PZRX) Delisted Grant (A) — $0 EDGAR
2015-05-11 INGN Mixed −384,695 -$179.5K EDGAR
2015-01-08 INGN Other (J) −735,767 $0 EDGAR
2015-01-06 INGN Sell (S) −7,946 -$246.2K EDGAR
2014-03-04 FLXN Grant (A) — $0 EDGAR
2014-02-20 FLXN Mixed +3,101,027 $4.00M EDGAR
Showing 61–68 of 68
Page 7 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.